sulfasalazine has been researched along with pulmicort in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Casolaro, V; Kim, J; Proud, D; Sanders, SP; Siekierski, ES | 1 |
| Van Gossum, A | 1 |
| Rutgeerts, PJ | 1 |
| Campieri, M | 1 |
| Brunner, W; Hollerweger, A; Macheiner, P | 1 |
| Feagan, BG; Sandborn, WJ | 1 |
| El Moutawakil, B; Gam, I; Rafai, MA; Rhimou, A; Slassi, I; Tahiri, JM | 1 |
| Hanauer, S; Lim, WC | 1 |
| Blonski, W; Buchner, AM; Lichtenstein, GR | 1 |
| Cheon, JH; Choi, CH; Jang, BI; Kim, YH; Lee, H; Lee, KM; Shin, SJ; Yang, SK; Ye, BD | 1 |
| Hanauer, S; Lim, WC; MacDonald, JK; Wang, Y | 1 |
| Clement, F; Coward, S; Ghosh, S; Hazlewood, G; Holmes, R; Kaplan, GG; Kuenzig, ME; McBrien, K; Panaccione, R; Rezaie, A; Seow, CH | 1 |
| Dulai, PS; Fumery, M; Murad, MH; Nguyen, NH; Prokop, LJ; Sandborn, WJ; Singh, S | 1 |
| Afif, W; Bernstein, CN; Bitton, A; Borgaonkar, M; Bressler, B; Chauhan, U; Halloran, B; Jones, J; Kennedy, E; Khanna, R; Leontiadis, GI; Loftus, EV; Marshall, JK; Meddings, J; Moayyedi, P; Murthy, S; Panaccione, R; Plamondon, S; Rosenfeld, G; Schwartz, D; Seow, CH; Steinhart, AH; Targownik, L; Williams, C | 1 |
| Ardizzone, S; Bezzio, C; Bosani, M; Carmagnola, S; Cassinotti, A; Chibbar, R; Dell'Era, A; Grillo, S; Landi, S; Maconi, G; Massari, A; Mezzina, N; Molteni, P; Pastorelli, L | 1 |
| Agrawal, M; Ananthakrishnan, AN; Claytor, J; Colombel, JF; Kumar, P; Ungaro, RC | 1 |
10 review(s) available for sulfasalazine and pulmicort
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Conventional treatment of Crohn's disease: objectives and outcomes.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Clinical Trials as Topic; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Mesalamine; Methotrexate; Prednisone; Quality of Life; Recurrence; Sulfasalazine; Treatment Outcome | 2001 |
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.
Topics: Acute Disease; Aspirin; Beclomethasone; Budesonide; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Glucocorticoids; Humans; Inflammatory Bowel Diseases; Prednisolone; Randomized Controlled Trials as Topic; Salicylates; Sulfasalazine | 2002 |
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Topics: Administration, Topical; Algorithms; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Controlled Clinical Trials as Topic; Crohn Disease; Gastrointestinal Agents; Glucocorticoids; Humans; Mesalamine; Sulfasalazine | 2003 |
Aminosalicylates for induction of remission or response in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Humans; Mesalamine; Randomized Controlled Trials as Topic; Remission Induction; Sulfasalazine | 2010 |
Update on the management of Crohn's disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Budesonide; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Mesalamine; Methotrexate; Natalizumab; Sulfasalazine; Tumor Necrosis Factor-alpha | 2011 |
Aminosalicylates for induction of remission or response in Crohn's disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Crohn Disease; Delayed-Action Preparations; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Randomized Controlled Trials as Topic; Sulfasalazine | 2016 |
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Bayes Theorem; Budesonide; Comparative Effectiveness Research; Crohn Disease; Humans; Induction Chemotherapy; Mesalamine; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Sulfasalazine; Treatment Outcome | 2017 |
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Network Meta-Analysis; Remission Induction; Sulfasalazine | 2018 |
Mild Crohn's Disease: Definition and Management.
Topics: Anti-Bacterial Agents; Budesonide; Crohn Disease; Enteral Nutrition; Humans; Remission Induction; Sulfasalazine | 2023 |
16 other study(ies) available for sulfasalazine and pulmicort
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection.
Topics: Bronchi; Budesonide; Calpain; Cell Line; Cytokines; Epithelial Cells; Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Interleukin-8; NF-kappa B; Nitric Oxide Donors; Promoter Regions, Genetic; Rhinovirus; RNA, Messenger; Sulfasalazine; Time Factors | 2000 |
[Therapy of chronic inflammatory intestinal disease].
Topics: Acute Disease; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Budesonide; Chronic Disease; Colectomy; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Drug Combinations; Gastrointestinal Agents; Glucosamine; Humans; Immunosuppressive Agents; Infliximab; Sulfasalazine | 2000 |
Suspicion of microscopic colitis raised by sonographic examination.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Budesonide; Colitis; Colon; Female; Humans; Loperamide; Middle Aged; Sulfasalazine; Ultrasonography | 2003 |
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Quality of Life; Sulfasalazine; Time Factors | 2005 |
[Crohn's disease presenting with recurrent acute polyradiculoneuropathy].
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Combined Modality Therapy; Crohn Disease; Diarrhea; Drug Combinations; Drug Therapy, Combination; Glucosamine; Humans; Malabsorption Syndromes; Male; Neural Conduction; Plasma Exchange; Polyradiculoneuropathy; Quadriplegia; Recurrence; Sulfasalazine | 2007 |
[Guidelines for the management of Crohn's disease].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Budesonide; Crohn Disease; Databases, Factual; Female; Fistula; Humans; Infliximab; Intestinal Perforation; Male; Mercaptopurine; Mesalamine; Methotrexate; Prednisolone; Pregnancy; Recurrence; Risk Factors; Severity of Illness Index; Sulfasalazine | 2012 |
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Azathioprine; Budesonide; Canada; Crohn Disease; Gastroenterology; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Induction Chemotherapy; Maintenance Chemotherapy; Mesalamine; Methotrexate; Prednisolone; Societies, Medical; Sulfasalazine; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Colitis, Ulcerative; Dosage Forms; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Logistic Models; Male; Mesalamine; Middle Aged; Multivariate Analysis; Retrospective Studies; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2019 |